AP Biosciences Doses First Patient in AP402 Phase 1/2 Trials
AP Biosciences has dosed the first patient in a Phase 1 trial of AP402, a novel T cell engager...
AP Biosciences has dosed the first patient in a Phase 1 trial of AP402, a novel T cell engager...
A study published in the Journal of Clinical Psychopharmacology revealed that patients with major depressive disorder experienced fewer psychiatric...
Achieve Life Sciences announced complete results from its ORCA-3 trial, published in JAMA Internal Medicine, demonstrating cytisinicline’s efficacy in...
Compass Therapeutics has initiated the first patient dosing in an Investigator Sponsored Trial (IST) at MD Anderson Cancer Center....
Elutia Inc. launched a clinical study to gather real-world data on patient outcomes using EluPro, its FDA-cleared antibiotic-eluting bioenvelope...
Regeneron Pharmaceuticals received a Complete Response Letter (CRL) from the FDA regarding its application to extend EYLEA HD’s dosing...
Sernova Biotherapeutics secured a CAD$4 million term loan from Navigate Private Yield Fund LP III. The loan, which matures...
ElectroCore, Inc. announced positive data from a study presented at the 2025 International Brain Injury Association World Congress, showing...
Can-Fite BioPharma announced that major U.S. medical centers are requesting FDA compassionate use approval for Namodenoson, its pancreatic cancer...
Alector and GSK have completed enrollment in their Phase 2 PROGRESS-AD trial, evaluating AL101/GSK4527226 for early-stage Alzheimer’s diseaseAlzheimer’s disease....